× Industry Reports Services Press Release Contact us About us

APAC Cell Line Development Market revenue to cross $2 Bn by 2027

 Request a sample

APAC Cell Line Development Market size is poised to reach USD 2 billion by 2027, according to a latest forecast report by Graphical Research.

Technological advancement in equipment will drive the business growth of cell line development. Adoption of new technology in cell line development will create new opportunities to biotechnology market players to expand their product portfolio and their geographical presence in Asia pacific region. For cell line development, flow cytometry plays important role. It reduces time consumption during research work and delivers accurate results. Most of the cell line development technologies used by biopharmaceutical companies based on methotrexate amplification technology and other.

The consumables & accessories segment is expected to garner more than 16% CAGR from 2021 to 2027. Consumables are those items that are used while performing any test such as bottles and reservoirs, cartridges, buffer and solutions, plates etc. to maximize efficiency in cell line development and drug discovery. In cell line development, laboratory requires several commodities such as reagents, consumables & accessories. Industry players supply wide range of consumables and accessories for the collection of cell lines, analysis and storage of sample during research work.

The non mammalian cell segment is accounted over 28% market share in 2020. In biotechnology and pharmaceutical industry, non- mammalian cell line is used in the production of therapeutic protein. Ongoing research on non-mammalian cell along with advance technological equipment support will boost the market size.

Browse detailed statistical insights from the report, “Asia Pacific Cell Line Development Market Forecast 2027 By Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research), By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope}, Accessories & Consumables), By Source (Mammalian, Non-mammalian {Insects, Amphibians}), By Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), I Research Report, Country Outlook (Japan, China, India, Australia, South Korea, Malaysia, Indonesia, Thailand, Singapore, Taiwan, Philippines, Vietnam), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @

https://www.graphicalresearch.com/industry-insights/1065/asia-pacific-cell-line-development-market

The hybridoma segment is anticipated to witness over 13.8% CAGR during the forecast period. Hybridoma technology is a multi-step method that generates continuous supply of monoclonal antibodies. After production of monoclonal antibodies these cell lines are used for therapeutic use and cancer diagnosis. Rising demand of cancer treatments will drive the market growth in coming years.

The toxicity testing segment is set to record a CAGR of around 14% through 2027. Toxicity testing is an essential method use during clinical trials or drug development to examine chemical compounds. Toxicity testing examines the effects of drug on living organisms under specific controlled laboratory condition. Increasing demand of toxicity testing in pharmaceutical industry will accelerate the market revenue.

The Japan cell line development industry is projected to exhibit more than 14% CAGR during assessment years. Ongoing research work in cell line development, adoption of innovative technology will raise market size. Rising regulatory approvals in Japan for cell line development will boost the market. Growing awareness among people for gene therapies for the treatment of chronic diseases will create new opportunities to Japanese market players to expand their product portfolio in the market.

The APAC cell line development market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2016 to 2027, for the following segments:

Asia Pacific Market, By Product

  • Reagents & media
  • Equipment
    • Incubators
    • Centrifuges
    • Bioreactors
    • Storage equipment
    • Microscopes
  • Accessories & consumables

Asia Pacific Market, By Source

  • Mammalian
  • Non-mammalian
    • Insects
    • Amphibians

Asia Pacific Market, By Cell Line Type

  • Recombinant cell lines
  • Hybridomas
  • Continuous cell lines
  • Primary cell lines

Asia Pacific Market, By Application

  • Bioproduction
  • Drug discovery
  • Toxicity testing
  • Tissue engineering
  • Research

The above information has been provided for the following countries:

  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Malaysia
    • Indonesia
    • Thailand
    • Singapore
    • Taiwan
    • Philippines
    • Vietnam